• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA restricts former chief’s activities

EMA restricts former chief’s activities

March 23, 2011
CenterWatch Staff

Former EMA executive director Thomas Lonngren is facing regulatory issues regarding his plans to consult for pharma companies.

After consumer groups and legislators for the European Parliament objected to Lonngren's new venture to "provide advice and counsel to the pharmaceutical industry," the EMA has decided to restrict his post-EMA activities. The agency said Lonngren would be prevented from contacting anyone at the agency for two years and asked for some details on his work for the industry, in order to "be able to fence off all unjustified allegations."

The EMA is also prohibiting Lonngren from taking an executive position at a pharma company for two years, while prohibiting his offering product-related advice on issues that involve the agency.

Lonngren was reprimanded for making a late declaration of his pharma-related work to the EMA. He sent the agency, which reviews drugs much like the FDA, a note in late December about his consulting work. "I am very conscious of my obligations and commitments to the EMA and can assure you that in my new role there will be no conflict of interest," he stated.

One of Lonngren's last acts as head of the EMA involved some criticism for the huge amount of money being spent on R&D relative to the actual new drug approvals that were made each year. "How many [new drugs] are approved each year—six, seven, eight, nine maybe? If the value of these few new drugs is worth 10, maybe 20 billion U.S. dollars, then where is the remainder of the $85 billion going?" asked Lonngren last December. "Maybe we could use this $60 billion in a better way?"

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing